AVR on Nasdaq
Anteris Technologies Global Corp.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with NutriBand Inc., CollPlant Biotechnologies Ltd or ENvue Medical, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 84% of the revenue Anteris Technologies Global Corp. broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $1.8M | $1.6M |
| Germany | $900.0K | $272.0K |
| Australia | $21.0K | $33.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue1¢$569.0K
- Research and development72¢$69.1M
- Selling, general and admin27¢$26.1M
Out of $1.9M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net sales | $1.9M | $2.7M |
| Cost of products sold | -$569.0K | -$1.4M |
| Research and development expense | -$69.1M | -$51.5M |
| Selling, general and administrative expense | -$26.1M | -$28.2M |
| Operating loss | -$93.9M | -$78.4M |
| Other non-operating income, net | $467.0K | $2.4M |
| Interest and amortization of debt discount and expense | -$73.0K | -$47.0K |
| Net foreign exchange (losses)/gains | -$744.0K | $1.4M |
| Debt issuance costs | $0 | -$465.0K |
| Loss on debt extinguishment | $0 | -$904.0K |
| Fair value movement of derivatives | $19.0K | -$61.0K |
| Loss before income taxes from continuing operations | -$94.2M | -$76.0M |
| Income tax (expense)/benefit | $0 | $0 |
| Loss after income tax | -$94.2M | -$76.0M |
| Non-controlling interests | -$81.0K | $324.0K |
| Stockholders of the Company | -$94.1M | -$76.3M |
| Basic loss per share (in Dollars per share) | -$2.55 | -$3.68 |
| Diluted loss per share (in Dollars per share) | -$2.55 | -$3.68 |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash, cash equivalents and restricted cash | $12.6M | $70.5M | $21.1M |
| Accounts receivable from customers, net of allowances | $32.0K | $208.0K | |
| Inventories | $152.0K | $513.0K | |
| Prepaid expenses | $642.0K | $640.0K | |
| Other current assets | $2.3M | $2.8M | |
| Total Current Assets | $15.7M | $74.7M | |
| Plant and equipment, net | $5.3M | $4.8M | |
| Operating lease right-of-use assets, net | $2.0M | $1.1M | |
| Intangible assets, net | $65.0K | $189.0K | |
| Total Non-Current Assets | $7.3M | $6.0M | |
| TOTAL ASSETS | $23.0M | $80.7M | |
| Accounts payable | $11.1M | $5.9M | |
| Accrued and other liabilities | $9.7M | $9.9M | |
| Current portion of operating lease liabilities | $566.0K | $747.0K | |
| Current portion of debt obligations | $16.0K | $3.0K | |
| Total Current Liabilities | $21.4M | $16.6M | |
| Operating lease liabilities | $1.7M | $645.0K | |
| Long-term debt obligations | $22.0K | ||
| Other liabilities | $177.0K | $812.0K | |
| Total Non-Current Liabilities | $1.9M | $1.5M | |
| TOTAL LIABILITIES | $23.2M | $18.0M | |
| Common Stock, $0.0001 par value, 400,000,000 shares authorized, 41,579,881 and 35,939,816 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $4.0K | $4.0K | |
| Preferred stock, $0.0001 par value, 40,000,000 shares authorized | $0 | $0 | |
| Additional paid in capital | $380.7M | $350.0M | |
| Accumulated other comprehensive loss | -$10.3M | -$10.9M | |
| Accumulated deficit | -$370.5M | -$276.4M | |
| TOTAL STOCKHOLDERS EQUITY | -$93.0K | $62.8M | |
| Non-controlling interests | -$160.0K | -$79.0K | -$403.0K |
| TOTAL EQUITY (DEFICIT) | -$253.0K | $62.7M | $18.9M |
| TOTAL LIABILITIES AND EQUITY | $23.0M | $80.7M | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 400.0M shares | 400.0M shares | |
| Common stock, shares outstanding (in Shares) | 41.6M shares | 35.9M shares | |
| Common stock, shares issued (in Shares) | 41.6M shares | 35.9M shares | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 40.0M shares | 40.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Loss after income tax | -$94.2M | -$76.0M |
| Depreciation and amortization expense | $1.7M | $1.5M |
| Equity-settled stock-based compensation | $7.8M | $6.5M |
| Loss on debt extinguishment | $0 | $904.0K |
| Debt issuance costs | $0 | $465.0K |
| Net foreign exchange losses/(gains) | $744.0K | -$1.4M |
| Other items | -$29.0K | $78.0K |
| Accounts receivable, prepayments and other assets | -$515.0K | -$911.0K |
| Inventories | $362.0K | -$71.0K |
| Accounts payable, accrued and other liabilities | $6.4M | $7.7M |
| NET CASH USED IN OPERATING ACTIVITIES | -$77.8M | -$61.2M |
| Acquisition of plant and equipment | -$2.0M | -$2.3M |
| Acquisition of intangible assets | $0 | -$14.0K |
| Deferred proceeds from sale of distribution rights | $1.4M | $0 |
| NET CASH USED IN INVESTING ACTIVITIES | -$596.0K | -$2.3M |
| Net proceeds from share issues | $25.8M | $119.6M |
| Share issue transaction costs | -$2.8M | -$3.9M |
| Tax withholding paid on stock option exercises | -$1.2M | $0 |
| Proceeds from issuance of convertible notes | $0 | $5.0M |
| Repayment of debt | -$1.2M | -$7.2M |
| Debt issuance costs paid | $0 | -$465.0K |
| Cash settlement of contingent options on debt | $0 | -$191.0K |
| Principal payments on finance lease obligations | -$14.0K | -$9.0K |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | $20.6M | $112.8M |
| Effect of exchange rate movements on cash, cash equivalents and restricted cash | -$38.0K | $57.0K |
| Net change during the year | -$57.9M | $49.4M |
| Cash received for research and development tax incentive | $594.0K | $962.0K |
| Operating cash outflows relating to operating leases | -$969.0K | -$834.0K |
| Non-cash additions to right-of-use assets and lease liabilities | $1.8M | $295.0K |
| Non-cash issue of shares/warrants to consultants for services provided | $735.0K | $430.0K |
Compare Anteris Technologies Global Corp. with another company
Recent filings
- Oct 8, 20264 PRIMARY DOCUMENT
- Oct 6, 20264 PRIMARY DOCUMENT
- Oct 1, 20264 PRIMARY DOCUMENT
- Sep 24, 2026424B3
- Sep 23, 20268-K
- Sep 21, 2026424B3
- Sep 17, 20268-K
- Sep 16, 20263
- Sep 16, 20264
- Sep 9, 2026424B3
- Sep 8, 20268-K
- Sep 3, 2026SCHEDULE 13G/A
- Sep 1, 20264 PRIMARY DOCUMENT
- Aug 20, 20264
- Aug 14, 2026SCHEDULE 13G/A
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5